To read the full story, subscribe or sign in.

Gilead's Quad regimen meets primary objective in phase II trial in HIV-infected adults

Jan. 7, 2010

No Comments

BioWorld Science HIV/AIDS

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 1, 2023.

Aurinia Therapeutics’ AUR-300 proven useful in systemic sclerosis

BioWorld Science

Aurinia Pharmaceuticals Inc. has investigated their CD206 ligand AUR-300 as a novel therapeutic agent for systemic sclerosis treatment.

‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

BioWorld

For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...

Waging the losing battle: Altimmune takes on challengers as Pfizer falls back

BioWorld

Altimmune Inc.’s peptide-based glucagon-like peptide-1/glucagon dual receptor agonist pemvidutide hiccupped in a phase I study earlier this year but has bounced...

Japan approves first self-amplifying mRNA COVID-19 vaccine from CSL, Arcturus

BioWorld

In a global first, Japan's Ministry of Health, Labor and Welfare has approved CSL Ltd.’s and Arcturus Therapeutics Inc.’s self-amplifying messenger RNA (sa-mRNA)...

Upgrade your daily dose of biopharma and medtech news

Gilead's Quad regimen meets primary objective in phase II trial in HIV-infected adults